XAIR News & Events

Beyond Cancer, a subsidiary of Beyond Air, announced updated follow-up data from its Phase 1 UNO trial, which are being presented at the American Association for Cancer Research, AACR, Annual Meeting 2026 in San Diego, California. The Phase 1 trial was a clinical proof-of-concept trial that assessed the intratumoral administration of UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions. As of February 2, 2026, six of ten patients remain alive between 22 to 40 months following a single UNO injection. While the study was not designed to assess efficacy and lacks a control arm, these observations may suggest prolonged survival in this heavily pretreated population. Interpretation of these results is limited by the small sample size and early-stage design. Two patients with triple negative breast cancer continue to demonstrate no evidence of disease, based on available imaging, testing, and clinical examinations. Treatment demonstrated a generally favorable safety and tolerability profile, with most treatment-related adverse events predominantly Grade 1 or Grade 2.

Beyond Air announced that Steve Lisi has resigned as CEO and stepped down from the board of directors, effective March 27 to pursue other opportunities. The board of directors has appointed Robert Goodman, the company's current chief commercial officer and director, as CEO, effective immediately.

Beyond Cancer, a subsidiary of Beyond Air, announced early signs of clinical activity and a favorable safety and tolerability profile from its Phase 1 clinical trial evaluating a single intratumoral UNO injection administered as monotherapy. These data were included in an Online Itinerary Planner issued for the American Association for Cancer Research annual meeting, which is scheduled to be held from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. The Phase 1 trial was a clinical proof-of-concept trial that assessed the intratumoral administration of UNO in patients with unresectable cutaneous or subcutaneous histologically confirmed primary or metastatic lesions. The trial enrolled ten heavily pretreated patients, including breast cancer, squamous cell carcinoma, and melanoma. Patients received a mean of 5.5 prior systemic therapies and 10.3 total cancer-directed treatments. Six patients received 25,000 ppm UNO and four patients received 50,000 ppm UNO. As of October 1, 2025, seven of ten patients remain alive between 19 to 37 months following a single UNO injection. One patient died of disease progression 25 months after treatment. Two patients with triple negative breast cancer have no evidence of disease. No deaths occurred within 12 weeks after treatment. Treatment demonstrated a favorable safety and tolerability profile, with most treatment-related adverse events limited to Grade 1. One treatment-related serious adverse event occurred during administration at 25,000 ppm; the event was not considered dose-limiting and resolved fully.

Beyond Air (XAIR) announced that the previously disclosed proposed transaction with XTL Biopharmaceuticals (XTLB) relating to Beyond Air's NeuroNOS subsidiary has been terminated. The companies entered into a letter of intent in January 2026 regarding a potential transaction in which XTL would acquire Beyond Air's majority ownership interest in NeuroNOS Ltd. The letter of intent expired on March 9, 2026, in accordance with its terms, and the parties did not enter into a definitive agreement. "While the proposed transaction will not proceed, Beyond Air remains committed to maximizing the value of the NeuroNOS platform," said Steve Lisi, CEO. "We continue to believe NeuroNOS represents a compelling opportunity based on its proprietary small-molecule platform and development programs targeting neurological disorders and oncology." Beyond Air will continue to evaluate strategic alternatives for NeuroNOS and remains focused on advancing its core nitric oxide platform and LungFit programs